Joel Jackson - BMO Capital Markets
Analyst
Hi. Good morning. When would you make a decision whether Colonsay would be ramped back up for 2017? What would be the factors around it? It seems like, considering some of the different things going on in the industry, the Rocanville proving run, the legacy ramp, your demand projection, you might not need the Colonsay tons for some time. And a second question as well which would be, you did not lower your dividend like one of your Canpotex partners did last week. You're running maybe around 200% payout ratio right now. What would have to happen for you to revise your dividend? Thanks.
James C. O'Rourke - President, Chief Executive Officer & Director: Okay, Joel, thank you for those questions. First, Colonsay, I mean, Colonsay's decision is clearly how do we meet our customer needs while optimizing our overall cost and cash output. So, we'll have to make another decision on Colonsay towards the end of the year. Our expectation at this stage is we will bring it up in January as per what we've previously announced. I mean, really the deciding factor there will be how much we think we'll need for our spring season and how well-positioned we are at the end of the year for that spring season. But at this stage, we're expecting we will bring up Colonsay in January. In terms of the dividend, look, at this point, we don't plan to cut our dividend as you've said. We see the fundamentals improving in the second half of the year which mitigates the need for a dividend cut. Now, if the markets don't improve or if they deteriorate, we may have to revisit the affordability of our dividend. However, just let me point out in the first half of the year, we generated sufficient cash to cover all of our commitments including capital and our dividend. So, our $1 billion of cash is still intact and our $2.5 billion liquidity buffer is still intact. So, we don't see an impending need to review our dividend at this stage. We leave that open that we may in the future. And, Rich, do you want to just add anything to that?
Richard L. Mack - Chief Financial Officer & Executive Vice President: Yes, I would just say, Joel, that obviously it's something that we closely monitor and we'll continue to closely monitor in the future, Joc noted. And we have a conservative liquidity buffer of $2.5 billion. Interestingly enough, we've never really dipped into the liquidity buffer in our history, and we've got over $1 billion of cash on the balance sheet. And at the same time, we're reducing our cash spend. So, we're lowering our capital, we're reducing our SG&A. We're maximizing working capital as much as we possibly can. And so this is something that we'll continue to review, obviously with the mindset of maintaining a solid investment-grade credit rating going forward.